Skip to main content

Psoriasis clinical trials at UCSF

7 in progress, 5 open to eligible people

Showing trials for
  • Dermatologic Research Evaluation and Monitoring of Sleep in Moderate-to-Severe Psoriasis

    open to eligible people ages 18 years and up

    Getting enough sleep is important for maximizing health and well-being. When it comes to health, sleep is as vital as regular exercise and eating a balanced diet. Not getting enough sleep can lead to health problems like heart attacks, diabetes, and even cancer. Since individuals with psoriasis have these same health problems, getting better sleep may help to keep them happier and healthier. This study will look at how individuals with psoriasis sleep and if their sleep is different than indivuduals without psoriasis.

    San Francisco, California

  • Guselkumab Immunogenetics

    open to eligible people ages 18 years and up

    This is a two-arm open-label study to evaluate the clinical and immunogenetic responses of patients with plaque or guttate psoriasis to treatment with guselkumab.

    San Francisco, California

  • Immunogenetic Profiling of Goeckerman Therapy in the Treatment of Psoriasis Vulgaris

    open to eligible people ages 18 years and up

    This study examines the effect of Goeckerman therapy (a combination of phototherapy and topical crude coal tar), crude coal tar alone, and phototherapy alone on the immunologic and genetic environment within psoriatic skin lesions.

    San Francisco, California

  • Light Treatment Effectiveness (LITE) Study

    open to eligible people ages 12 years and up

    To compare the effectiveness, safety (tolerability), and duration of treatment response at 12 weeks of home versus office-based narrowband ultraviolet B phototherapy for the treatment of psoriasis

    San Francisco, California and other locations

  • Predicting Inflammatory Skin Disease Response to IL-23 Blockade

    open to eligible people ages 18 years and up

    This study examines the effect of IL-23 blockade with Tildrakizumab on the immune cells of psoriatic skin lesions.

    San Francisco, California

  • Chronic Plaque Psoriasis (Ps) Registry

    Sorry, in progress, not accepting new patients

    The purpose of this study is to evaluate the long-term safety of Humira® in Adult Patients with Chronic Plaque Psoriasis (Ps).

    San Francisco, California and other locations

  • Psoriatic Immune Response to Tildrakizumab

    Sorry, not yet accepting patients

    This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.

    San Francisco, California

Our lead scientists for Psoriasis research studies include .

Last updated: